ES2969968T3 - Uso de anticuerpos anti-CD40 para tratamiento de nefritis lúpica - Google Patents

Uso de anticuerpos anti-CD40 para tratamiento de nefritis lúpica Download PDF

Info

Publication number
ES2969968T3
ES2969968T3 ES16763663T ES16763663T ES2969968T3 ES 2969968 T3 ES2969968 T3 ES 2969968T3 ES 16763663 T ES16763663 T ES 16763663T ES 16763663 T ES16763663 T ES 16763663T ES 2969968 T3 ES2969968 T3 ES 2969968T3
Authority
ES
Spain
Prior art keywords
antibody
seq
antibodies
sequence
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16763663T
Other languages
English (en)
Spanish (es)
Inventor
Scott Ronald Brodeur
Thomas B Freeman
Gerald Henry Nabozny
Meera RAMANUJAM
Paul Scholl
Juergen STEFFGEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Application granted granted Critical
Publication of ES2969968T3 publication Critical patent/ES2969968T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES16763663T 2015-09-01 2016-08-31 Uso de anticuerpos anti-CD40 para tratamiento de nefritis lúpica Active ES2969968T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562212810P 2015-09-01 2015-09-01
US201562257336P 2015-11-19 2015-11-19
US201662287587P 2016-01-27 2016-01-27
PCT/US2016/049558 WO2017040566A1 (en) 2015-09-01 2016-08-31 Use of anti-cd40 antibodies for treatment of lupus nephritis

Publications (1)

Publication Number Publication Date
ES2969968T3 true ES2969968T3 (es) 2024-05-23

Family

ID=56896810

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16763663T Active ES2969968T3 (es) 2015-09-01 2016-08-31 Uso de anticuerpos anti-CD40 para tratamiento de nefritis lúpica

Country Status (16)

Country Link
US (3) US20170058038A1 (https=)
EP (1) EP3344655B1 (https=)
JP (2) JP2018529661A (https=)
KR (1) KR20180039172A (https=)
CN (1) CN107922501A (https=)
AU (1) AU2016317028B2 (https=)
BR (1) BR112018001907A2 (https=)
CA (1) CA2993996A1 (https=)
CL (1) CL2018000317A1 (https=)
DK (1) DK3344655T5 (https=)
ES (1) ES2969968T3 (https=)
HU (1) HUE063528T2 (https=)
MX (1) MX390653B (https=)
PH (1) PH12018500445B1 (https=)
PL (1) PL3344655T3 (https=)
WO (1) WO2017040566A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US20200299400A1 (en) * 2017-05-25 2020-09-24 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
WO2020006347A1 (en) * 2018-06-29 2020-01-02 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies for use in treating autoimmune disease
US20240254248A1 (en) * 2018-11-30 2024-08-01 Jiangsu Hengrui Medicine Co., Ltd. Cd40 antibody pharmaceutical composition and use thereof
AU2022214319A1 (en) 2021-01-28 2023-08-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
WO2006073443A2 (en) * 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-cd40 monoclonal antibodies and methods for their use
US8303955B2 (en) * 2005-05-26 2012-11-06 Seattle Genetics, Inc. Humanized anti-CD40 antibodies and their methods of use
AR060487A1 (es) * 2006-04-21 2008-06-18 Xoma Technology Ltd Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
HUE049849T2 (hu) * 2010-03-31 2020-10-28 Boehringer Ingelheim Int Anti-CD40 antitestek
ES2709654T3 (es) * 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation

Also Published As

Publication number Publication date
CN107922501A (zh) 2018-04-17
US20170058038A1 (en) 2017-03-02
JP2021185169A (ja) 2021-12-09
CA2993996A1 (en) 2017-03-09
EP3344655A1 (en) 2018-07-11
EP3344655B1 (en) 2023-07-26
PH12018500445B1 (en) 2022-08-10
AU2016317028B2 (en) 2021-09-09
MX2018002447A (es) 2018-06-15
HUE063528T2 (hu) 2024-01-28
PL3344655T3 (pl) 2024-02-19
CL2018000317A1 (es) 2018-07-20
AU2016317028A1 (en) 2018-02-22
US20230265203A1 (en) 2023-08-24
DK3344655T5 (da) 2024-10-07
PH12018500445A1 (en) 2018-09-10
MX390653B (es) 2025-03-21
KR20180039172A (ko) 2018-04-17
JP2018529661A (ja) 2018-10-11
US20190177420A1 (en) 2019-06-13
BR112018001907A2 (pt) 2018-09-25
WO2017040566A1 (en) 2017-03-09
DK3344655T3 (da) 2023-10-09

Similar Documents

Publication Publication Date Title
ES2969968T3 (es) Uso de anticuerpos anti-CD40 para tratamiento de nefritis lúpica
US20210317201A1 (en) Anti-il-23 antibodies
JP6289375B2 (ja) 抗ｉｌ−３６ｒ抗体
RS67443B1 (sr) Anti-pd-1 antitela za upotrebu u lečenju kancera
US20220073616A1 (en) Methods of administering anti-tim-3 antibodies
US12221485B2 (en) TMEM219 antibodies and therapeutic uses thereof
BR112021016537A2 (pt) Terapia de combinação envolvendo anticorpos anti-cd39 e anticorpos anti-pd-1 ou anti-pd-l1
JP2024540395A (ja) Ｃｏｖｉｄ－１９を治療及び予防するための組成物
JP2023537078A (ja) ＣＯＶＩＤ－１９を治療及び防止するためのＳＡＲＳ－ＣｏＶ－２抗体
US20240209095A1 (en) Anti-human pd-l1 antibodies and their uses
TWI901797B (zh) 抗-sema3a抗體及其用於治療視網膜栓塞疾病之用途
EA039944B1 (ru) Применение антител к cd40 для лечения волчаночного нефрита
KR20260013511A (ko) 암 치료를 위한 조합 요법
JP2025523477A (ja) インテグリンアルファ１１ベータ１に対する抗体及びその使用
HK40128870A (zh) 抗人类pd-l1抗体及其用途
BR122025002178A2 (pt) Anticorpos para cd3 e bcma, e proteínas de ligação biespecíficas feitas a partir dos mesmos